Journal of Assisted Reproduction and Genetics

, Volume 33, Issue 9, pp 1185–1194 | Cite as

Serum hCG-β levels of postovulatory day 12 and 14 with the sequential application of hCG-β fold change significantly increased predictability of pregnancy outcome after IVF-ET cycle

  • Nayoung Sung
  • Joanne Kwak-Kim
  • H. S. Koo
  • K. M. YangEmail author
Assisted Reproduction Technologies



To investigate hCG-β level on postovulatory day (POD) 12 and its fold increase as predictors for pregnancy outcome after in vitro fertilization (IVF) cycles.


A retrospective cohort study was performed in total 1408 fresh and 598 frozen cycles between November 2008 and October 2011, which resulted in biochemical pregnancy, early pregnancy loss, or live birth of singleton pregnancy. The serum hCG-β levels of POD 12 and 14 were compared among biochemical pregnancy, early pregnancy loss, and live birth groups. The cutoff values of POD 12 and 14 hCG-β levels and the degree of hCG-β increase from POD 12 to 14 were determined for each pregnancy outcome.


POD 12 and 14 hCG-β levels stratified based on pregnancy outcomes were significantly different among the biochemical pregnancy, early pregnancy loss, and live birth in both fresh and frozen cycles. Serum hCG-β levels of POD 12 and 14 and the fold increase of hCG-β levels from POD 12 to 14 significantly predict pregnancy outcomes after fresh and frozen cycles. Among these, the cutoff value of POD 14 hCG-β had the highest sensitivity and positive predictive value (PPV). In fresh cycles, the cutoff values of POD 12 and 14 serum hCG-β levels for clinical pregnancies were 30.2 mIU/mL (sensitivity 81.3 %, specificity 79.6 %, and PPV 92.3 %) and 70.5 mIU/mL (sensitivity 88.4 %, specificity 85.2 %, and PPV 94.7 %). In pregnancies with POD 12 serum hCG-β levels ≥30.2 mIU/mL, the cutoff level of increase of hCG-β for clinical pregnancy was 2.56 (sensitivity 73.6 %, specificity 72.4 %, and PPV 97.8 %). Sequential application of cutoff values such as POD 12 hCG-β and fold increase of hCG-β improved predictability of pregnancy outcome as compared with that of POD 12 hCG-β alone. The cutoff values of POD 12 and 14 serum hCG-β levels for live birth were 40.5 mIU/mL (sensitivity 75.2 %, specificity 72.6 %, PPV 78.9 %) and 104.5 mIU/mL (sensitivity 80.3 %, specificity 74.1 %, PPV 80.8 %). In the frozen cycles, the cutoff values of POD 12 and 14 serum hCG-β level for clinical pregnancy were 31.5 IU/L (sensitivity 80.4 %, specificity 71.1 % and PPV 90 %) and 43.5 mIU/mL (sensitivity 72.6 %, specificity 71.7 %, PPV 77.2 %). In pregnancies with POD 12 serum hCG-β level ≥31.5 mIU/mL, the cutoff value for fold increase of hCG-β was 2.38 for clinical pregnancy (sensitivity 81.6 %, specificity 71.4 % and PPV 87.9 %). The cutoff values of POD 12 and 14 for live birth were 43.5 mIU/mL (sensitivity 72.6 %, specificity 71.7 %, PPV 77.2 %) and 101.6 mIU/mL (sensitivity 79.6 %, specificity 71.1 %, PPV 78.4 %). Sequential application of cutoff values for POD 12 hCG-β level and fold increase of hCG-β significantly increased PPV for live birth but not clinical pregnancy in frozen cycles.


Early prediction of pregnancy outcome by using POD 12 and 14 cutoff levels and sequential application of cutoff value of fold increase could provide appropriate reference to health care providers to initiate earlier management of high-risk pregnancies and precise follow-up of abnormal pregnancies.


IVF hCG-beta Pregnancy outcome Live birth Biochemical pregnancy 


Author’s roles

NS collected the data and analyzed it. JKK supervised the data analysis, study design, and writing of the manuscript.

HSK collected the data. KM Y supervised data collection, analysis, and designed the study.

Compliance with ethical standards


The study was supported by Department of Obstetrics and Gynecology, Cheil General Hospital and Women’s Healthcare Center, Dankook University College of Medicine, Seoul, Korea.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10815_2016_744_MOESM1_ESM.pdf (297 kb)
Supplemental Table 1 (PDF 296 kb)


  1. 1.
    Cohen J, Alikani M, Bisignano A. Past performance of assisted reproduction technologies as a model to predict future progress: a proposed addendum to Moore’s law. Reprod Biomed Online. 2012;25(6):585–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Shamonki MI, Frattarelli JL, Bergh PA, Scott RT. Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization: an analysis of 6021 pregnancies. Fertil Steril. 2009;91(5):1760–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Morgan FJ, Birken S, Canfield RE. The amino acid sequence of human chorionic gonadotropin. The alpha subunit and beta subunit. J Biol Chem. 1975;250(13):5247–58.PubMedGoogle Scholar
  4. 4.
    Handschuh K, Guibourdenche J, Tsatsaris V, Guesnon M, Laurendeau I, Evain-Brion D, et al. Human chorionic gonadotropin expression in human trophoblasts from early placenta: comparative study between villous and extravillous trophoblastic cells. Placenta. 2007;28(2–3):175–84.CrossRefPubMedGoogle Scholar
  5. 5.
    Braunstein GD, Rasor JL, Engvall E, Wade ME. Interrelationships of human chorionic gonadotropin, human placental lactogen, and pregnancy-specific beta 1-glycoprotein throughout normal human gestation. Am J Obstet Gynecol. 1980;138(8):1205–13.PubMedGoogle Scholar
  6. 6.
    Dokras A, Sargent IL, Gardner RL, Barlow DH. Human trophectoderm biopsy and secretion of chorionic gonadotrophin. Hum Reprod (Oxford, England). 1991;6(10):1453–9.Google Scholar
  7. 7.
    Fishel SB, Edwards RG, Evans CJ. Human chorionic gonadotropin secreted by preimplantation embryos cultured in vitro. Science. 1984;223(4638):816–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Hay DL, Lopata A. Chorionic gonadotropin secretion by human embryos in vitro. J Clin Endocrinol Metab. 1988;67(6):1322–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Adjaye J, Bolton V, Monk M. Developmental expression of specific genes detected in high-quality cDNA libraries from single human preimplantation embryos. Gene. 1999;237(2):373–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Ramu S, Acacio B, Adamowicz M, Parrett S, Jeyendran RS. Human chorionic gonadotropin from day 2 spent embryo culture media and its relationship to embryo development. Fertil Steril. 2011;96(3):615–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Butler SA, Luttoo J, Freire MO, Abban TK, Borrelli PT, Iles RK. Human chorionic gonadotropin (hCG) in the secretome of cultured embryos: hyperglycosylated hCG and hCG-free beta subunit are potential markers for infertility management and treatment. Reprod Sci. 2013;20(9):1038–45.CrossRefPubMedGoogle Scholar
  12. 12.
    Dor J, Rudak E, Rotmench S, Levran D, Blankstein J, Lusky A, et al. The role of early post-implantation beta-HCG levels in the outcome of pregnancies following in-vitro fertilization. Hum Reprod (Oxford, England). 1988;3(5):663–7.Google Scholar
  13. 13.
    Hay DL, Gronow M, Lopata A, Brown JB. Monitoring early production of chorionic gonadotrophin (HCG) following in vitro fertilization and embryo transfer. Aust N Z J Obstet Gynaecol. 1984;24(3):206–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Kadar N, Romero R. Observations on the log human chorionic gonadotropin-time relationship in early pregnancy and its practical implications. Am J Obstet Gynecol. 1987;157(1):73–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Lenton EA, Hooper M, King H, Kumar A, Monks N, Verma S, et al. Normal and abnormal implantation in spontaneous in-vivo and in-vitro human pregnancies. J Reprod Fertil. 1991;92(2):555–65.CrossRefPubMedGoogle Scholar
  16. 16.
    Liu HC, Kreiner D, Muasher SJ, Jones G, Jones Jr H, Rosenwaks Z. Beta-human chorionic gonadotropin as a monitor of pregnancy outcome in in vitro fertilization-embryo transfer patients. Fertil Steril. 1988;50(1):89–94.CrossRefPubMedGoogle Scholar
  17. 17.
    Yamashita T, Okamoto S, Thomas A, MacLachlan V, Healy DL. Predicting pregnancy outcome after in vitro fertilization and embryo transfer using estradiol, progesterone, and human chorionic gonadotropin beta-subunit. Fertil Steril. 1989;51(2):304–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Heiner JS, Kerin JF, Schmidt LL, Wu TC. Can a single, early quantitative human chorionic gonadotropin measurement in an in vitro fertilization-gamete intrafallopian transfer program predict pregnancy outcome? Fertil Steril. 1992;58(2):373–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Glatstein IZ, Hornstein MD, Kahana MJ, Jackson KV, Friedman AJ. The predictive value of discriminatory human chorionic gonadotropin levels in the diagnosis of implantation outcome in in vitro fertilization cycles. Fertil Steril. 1995;63(2):350–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Qasim SM, Callan C, Choe JK. The predictive value of an initial serum beta human chorionic gonadotropin level for pregnancy outcome following in vitro fertilization. J Assist Reprod Genet. 1996;13(9):705–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen CD, Ho HN, Wu MY, Chao KH, Chen SU, Yang YS. Paired human chorionic gonadotrophin determinations for the prediction of pregnancy outcome in assisted reproduction. Hum Reprod. 1997;12(11):2538–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Bjercke S, Tanbo T, Dale PO, Morkrid L, Abyholm T. Human chorionic gonadotrophin concentrations in early pregnancy after in-vitro fertilization. Hum Reprod. 1999;14(6):1642–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Urbancsek J, Hauzman E, Fedorcsak P, Halmos A, Devenyi N, Papp Z. Serum human chorionic gonadotropin measurements may predict pregnancy outcome and multiple gestation after in vitro fertilization. Fertil Steril. 2002;78(3):540–2.CrossRefPubMedGoogle Scholar
  24. 24.
    Poikkeus P, Hiilesmaa V, Tiitinen A. Serum HCG 12 days after embryo transfer in predicting pregnancy outcome. Hum Reprod. 2002;17(7):1901–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Alahakoon TI, Crittenden J, Illingworth P. Value of single and paired serum human chorionic gonadotropin measurements in predicting outcome of in vitro fertilisation pregnancy. Aust N Z J Obstet Gynaecol. 2004;44(1):57–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Winter E, Wang J, Davies MJ, Norman R. Early pregnancy loss following assisted reproductive technology treatment. Hum Reprod. 2002;17(12):3220–3.CrossRefPubMedGoogle Scholar
  27. 27.
    Cho YJ, Kim JY, Song IO, Lee HS, Lim CK, Koong MK, et al. Does blastomere biopsy in preimplantation genetic diagnosis affect early serum beta-hCG levels? Clin Exp Reprod Med. 2011;38(1):31–6.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    The Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the Society for Assisted Reproductive Technology. Guidelines on number of embryos transferred. Fertil Steril. 2009;92(5):1518–9.CrossRefGoogle Scholar
  29. 29.
    Annan JJ, Gudi A, Bhide P, Shah A, Homburg R. Biochemical pregnancy during assisted conception: a little bit pregnant. J Clin Med Res. 2013;5(4):269–74.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Confino E, Demir RH, Friberg J, Gleicher N. The predictive value of hCG beta subunit levels in pregnancies achieved by in vitro fertilization and embryo transfer: an international collaborative study. Fertil Steril. 1986;45(4):526–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Lawler CC, Budrys NM, Rodgers AK, Holden A, Brzyski RG, Schenken RS. Serum beta human chorionic gonadotropin levels can inform outcome counseling after in vitro fertilization. Fertil Steril. 2011;96(2):505–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Reljič M, Knez J, Vlaisavljević V. Human chorionic gonadotropin levels are equally predictive for pregnancy outcome after fresh and vitrified-warmed blastocyst transfer. J Assist Reprod Genet. 2013;30(11):1459–63.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Raty R, Virtanen A, Koskinen P, Anttila L, Forsstrom J, Laitinen P, et al. Serum free beta-HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down’s syndrome. Hum Reprod. 2002;17(2):481–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Hui PW, Tang MH, Lam YH, Ng EH, Yeung WS, Ho PC. Maternal serum hCG and alpha-fetoprotein levels in pregnancies conceived after IVF or ICSI with fresh and frozen-thawed embryos. Hum Reprod. 2003;18(3):572–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Kathiresan AS, Cruz-Almeida Y, Barrionuevo MJ, Maxson WS, Hoffman DI, Weitzman VN, et al. Prognostic value of beta-human chorionic gonadotropin is dependent on day of embryo transfer during in vitro fertilization. Fertil Steril. 2011;96(6):1362–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Orasanu B, Jackson KV, Hornstein MD, Racowsky C. Effects of culture medium on HCG concentrations and their value in predicting successful IVF outcome. Reprod Biomed Online. 2006;12(5):590–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Gold RS, Azem F, Yovel I, Wagman I, Amit A, Lessing JB. Does ICSI affect early serum beta-HCG in pregnancies achieved after IVF? Hum Reprod (Oxford, England). 2000;15(6):1221–4.CrossRefGoogle Scholar
  38. 38.
    al-Sebai MA, Diver M, Hipkin LJ. The role of a single free beta-human chorionic gonadotrophin measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability. Hum Reprod (Oxford, England). 1996;11(4):881–8.CrossRefGoogle Scholar
  39. 39.
    Singh N, Goyal M, Malhotra N, Tiwari A, Badiger S. Predictive value of early serum beta-human chorionic gonadotrophin for the successful outcome in women undergoing in vitro fertilization. J Hum Reprod Sci. 2013;6(4):245–7.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Sugantha SE, Webster S, Sundar E, Lenton EA. Predictive value of plasma human chorionic gonadotrophin following assisted conception treatment. Hum Reprod. 2000;15(2):469–73.CrossRefPubMedGoogle Scholar
  41. 41.
    Stone BA, Vargyas JM, Ringler GE, March CM, Marrs RP. The rate at which serum total β-subunit human chorionic gonadotropin increases after embryo transfer is a predictor of the viability of pregnancy and an identifier of determinants of pregnancy. Fertil Steril. 2006;86(6):1626–33.CrossRefPubMedGoogle Scholar
  42. 42.
    Batzer FR, Weiner S, Corson SL, Schlaff S, Otis C. Landmarks during the first forty-two days of gestation demonstrated by the beta-subunit of human chorionic gonadotropin and ultrasound. Am J Obstet Gynecol. 1983;146(8):973–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Badawy AM, Khiary M, Sherif LS, Hassan M, Ragab A, Abdelall I. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol. 2008;28(3):280–4.CrossRefPubMedGoogle Scholar
  44. 44.
    Fawzy M, Shokeir T, El-Tatongy M, Warda O, El-Refaiey AA, Mosbah A. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet. 2008;278(1):33–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Han AR, Ahn H, Vu P, Park JC, Gilman-Sachs A, Beaman K, et al. Obstetrical outcome of anti-inflammatory and anticoagulation therapy in women with recurrent pregnancy loss or unexplained infertility. Am J Reprod Immunol. 2012;68(5):418–27.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Nayoung Sung
    • 1
    • 2
  • Joanne Kwak-Kim
    • 1
  • H. S. Koo
    • 2
  • K. M. Yang
    • 2
    Email author
  1. 1.Reproductive Medicine, Department of Obstetrics and Gynecology, Chicago Medical SchoolRosalind Franklin University of Medicine and ScienceChicagoUSA
  2. 2.Department of Obstetrics and Gynecology, Cheil General Hospital and Women’s Healthcare CenterDankook University College of MedicineSeoulSouth Korea

Personalised recommendations